Pharmacologic treatments for opioid dependence: Detoxification and maintenance options

Dialogues in Clinical Neuroscience

Volumn 9, Issue 4, 2007, Pages 455-470

  Kleber, Herbert D ^a,b  

^a College of Physicians and Surgeons ^*  (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Buprenorphine; Clonidine; Detoxification; Maintenance; Methadone; Naltrexone; Opioid dependence; Pharmacologic treatment

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; BISMUTH SALICYLATE; BUPRENORPHINE; CLONAZEPAM; CLONIDINE; LOFEXIDINE; METHADONE; NALOXONE; NALTREXONE; NONSTEROID ANTIINFLAMMATORY AGENT; ONDANSETRON; PROCHLORPERAZINE; TRAZODONE; ZOLPIDEM;

CONSTIPATION; DRUG DETOXIFICATION; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHORIA; GENERAL ANESTHESIA; HEADACHE; HUMAN; HYPOTENSION; LABORATORY TEST; MAINTENANCE THERAPY; NAUSEA; OPIATE ADDICTION; ORGASM DISORDER; PAIN; PATIENT COUNSELING; PATIENT SELECTION; PREGNANCY; REVIEW; SEXUAL INTEREST; SIDE EFFECT; SWEATING; URINALYSIS; URINE RETENTION; WITHDRAWAL SYNDROME;

ANALGESICS, OPIOID; ANIMALS; BUPRENORPHINE; HUMANS; METABOLIC DETOXICATION, DRUG; METHADONE; NALOXONE; OPIOID-RELATED DISORDERS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 38549099015     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (174)

1. Stein MD, Friedmann PD. Optimizing opioid detoxification: rearranging deck chairs on the Titanic. J Addict Dis. 2007;26:1-2.
2. Davison JW, Sweeney ML, Bush KR, et al. Outpatient treatment engagement and abstinence rates following inpatient opioid detoxification. J Addict Dis. 2006;25:27-35.
3. O'Connor PG. Methods of detoxification and their role in treating patients with opioid dependence. JAMA. 2005;294:961-963.
4. McCambridge J, Gossop M, Beswick T, et al. In-patient detoxification procedures, treatment retention, and post-treatment opiate use: comparison of lofexidine + naloxone, lofexidine + placebo, and methadone. Drug Alcohol Depend. 2007;88:91-95.
5. Joe GW, Simpson DD, Broome KM. Retention and patient engagement models for different treatment modalities in DATOS. Drug Alcohol Depend. 1999;57:113-125.
6. Kleber H. Opioids: detoxification. In: Galanter M, Kleber, HD, eds. Textbook of Substance Abuse Treatment. 2nd ed. Washington, DC: American Psychiatric Press; 1999;251-269.
7. Martin WR, Jasinski DR. Physiological parameters of morphine dependence in man: tolerance, early abstinence, protracted abstinence. J Psychiatr Res. 1969;7:9-17.
8. Dart R, Woody, G, Kleber H. Prescribing methadone as an analgesic. Ann Intern Med. 2005;143:620.
9. Strang J, Gossop M. Comparison of linear versus inverse exponential methadone reduction curves in the detoxification of opiate addicts. Addict Behav. 1990;15:541-547.
10. Gossop M, Johns A, Green L. Opiate withdrawal: inpatient versus outpatient programmes and preferred versus random assignment to treatment. BMJ (Clin Res Ed). 1986;293:103-104.
11. Berg ML, Idrees U, Ding R, et al. Evaluation of the use of buprenorphine for opioid withdrawal in an emergency department. Drug Alcohol Depend. 2007;86:239-244.
12. Lintzeris N, Bell J, Bammer G, et al. A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal. Addiction. 2002:1395-1404.
13. Lopatko OV, White JM, Huber A, et al. Opioid effects and opioid withdrawal during a 24 h dosing interval in patients maintained on buprenorphine. Drug Alcohol Depend. 2003:317-322.
14. Breen CL, Harris SJ, Lintzeris N, et al. Cessation of methadone maintenance treatment using buprenorphine: transfer from methadone to buprenorphine and subsequent buprenorphine reductions. Drug Alcohol Depend. 2003;71:49-55.
15. Collins ED, Kleber HD, Whittington RA, et al. Anesthesia-assisted vs. buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction. A randomized trial. JAMA. 2005;294:903-913.
16. Bochud Tornay C, Favrat B, Monnat M, et al. Ultra-rapid opiate detoxification using deep sedation and prior oral buprenorphine preparation: long-term results. Drug Alcohol Depend. 2003;69:283-288.
17. Gowing L, Ali, R, White, J. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev. 2006;CD00205.
18. Gold MS, Redmond DE, Jr., Kleber HD. Clonidine in opiate withdrawal. Lancet. 1978;1:929-30.
19. Charney DS, Heninger GR, Kleber HD. The combined use of clonidine and naltrexone as a rapid, safe, and effective treatment of abrupt withdrawal from methadone. Am J Psychiatry. 1986;143:831-837.
20. O'Connor PG, Carroll KM, Shi JM, et al. Three methods of opioid detoxification in a primary care setting. A randomized trial. Ann Intern Med. 1997;127:526-530.
21. Kleber HD, Riordan CE, Rounsaville B, et al. Clonidine in outpatient detoxification from methadone maintenance. Arch Gen Psychiatry. 1985;42:391-394.
22. Jasinski DR, Johnson RE, Kocher,TR. Clonidine in morphine withdrawal: differential effects on signs and symptoms. Arch Gen Psychiatry. 1985:1063-1066.
23. Carnwath T, Hardman, J. Randomized double-blind comparison of lofexidine and clonidine in the outpatient treatment of opiate withdrawal. Drug Alcohol Depend. 1998:251-254.
24. Kahn A, Mumford, JP, Rogers, GA, et al. Double blind study of lofexidine and clonidine in the detoxification of oopiate addicts in hospital. Drug Alcohol Depend. 1997:57-61.
25. Buntwal N, Bearn J, Gossop M, et al. Naltrexone and lofexidine combination treatment compared with conventional lofexidine treatment for in-patient opiate detoxification. Drug Alcohol Depend. 2000;59:183-188.
26. Beam J, Gossop M, Strang J. Accelerated lofexidine treatment regimen compared with conventional lofexidine and methadone treatment for inpatient opiate detoxification. Drug Alcohol Depend. 1998;50:227-232.
27. Bearn J, Bennett J, Martin T, et al. The impact of naloxone/lofexidine combination treatment on the opiate withdrawal syndrome. Addict Biol. 2001;6:147-156.
28. Strang J, Bearn J, Gossop M. Lofexidine for opiate detoxification: review of recent randomised and open controlled trials. Am J Addict. 1999;8:337-348.
29. Riordan CE, Kleber HD. Rapid opiate detoxification with clonidine and naloxone. Lancet. 1980;1:1079-1080.
30. O'Connor PG, Waugh, M.E., Carroll, K.M., et al. Primary care-based ambulatory opioid detoxification: the results of a clinical trial. J Gen Intern Med. 1995:255-260.
31. Vining E, Kosten TR, Kleber HD. Clinical utility of rapid clonidine-naltrexone detoxification for opioid abusers. Br J Addict. 1988;83:567-575.
32. O'Connor PG, Kosten TR. Rapid and ultrarapid opioid detoxification techniques. JAMA. 1998;279:229-234.
33. Loimer N, Schmid RW, Presslich O, et al. Continuous naloxone administration suppresses opiate withdrawal symptoms in human opiate addicts during detoxification treatment. J Psychiatr Res. 1989;23:81-86.
34. Loimer N, Lenz K, Schmid R, et al. Technique for greatly shortening the transition from methadone to naltrexone maintenance of patients addicted to opiates. Am J Psychiatry. 1991;148:933-935.
35. Loimer N, Hofmann P, Chaudhry H. Ultrashort noninvasive opiate detoxification. Am J Psychiatry. 1993;150:839.
36. Seoane A, Carrasco G, Cabre L, et al. Efficacy and safety of two new methods of rapid intravenous detoxification in heroin addicts previously treated without success. Br J Psychiatry. 1997;171:340-345.
37. Brewer C. Ultra-rapid antagonist-precipitated opiate detoxification under general anesthesia or sedation. Addict Biol. 1997;2:291-302.
38. Kleber HD. Ultrarapid opiate detoxification. Addiction. 1998;93:1629-1633.
39. Scherbaum N, Klein S, Kaube H, et al. Alternative strategies of opiate detoxification: evaluation of the so-called ultra-rapid detoxification. Pharmacopsychiatry. 1998:205-209.
40. Cucchia AT, Monnat M, Spagnoli J, et al. Ultra-rapid opiate detoxification using deep sedation with oral midazolam: short and long-term results. Drug Alcohol Depend. 1998;52:243-250.
41. Spanagel R, Sillaber I, Zieglgansberger W, et al. Acamprosate suppresses the expression of morphine-induced sensitization in rats but does not affect heroin self-administration or relapse induced by heroin or stress. Psychopharmacology (Berl). 1998;139:391-401.
42. McGregor C, Ali, R, White, JM, et al. A comparison of antagonist-precipitated withdrawal under anesthesia to standard inpatient withdrawal as a precurser to maintenance naltrexone treatment in heroin users: outcomes at 6 and 12 months. Drug Alcohol Depend. 2002:5-14.
43. DeJong CAJ, Laheij RJF, Krabbe PFM. General anesthesia does not improve outcome in opioid antagonist detoxification treatment: a randomized controlled tiral. Addiction. 2005;100:206-215.
44. Hamilton RJ, Olmedo, RE, Shah S, et al. Complications of ultra-rapid opioid detoxification with subcutaneous naltrexone pellets. Acad Emerg Med. 2002:63-68.
45. Whittington RA, Collins ED, Kleber HD. Rapid opioid detoxification during general anesthesia: is death not a significant outcome? Anesthesiology. 2000;93:1363-1364.
46. Gold CG, Cullen DJ, Gonzales S, et al. Rapid opioid detoxification during general anesthesia: a review of 20 patients. Anesthesiology. 1999;91:1639-1647.
47. Dyer C. Addict died after rapid opiate detoxification. BMJ. 1998;316:170.
48. Jarvis MA, Schnoll SH. Methadone treatment during pregnancy. J Psychoactive Drugs. 1994;26:155-161.
49. Collins SL, Kleber H. Opioids: detoxification. In: Galanter M, Kleber, HD, eds. Textbook of Substance Abuse Treatment. 3rd ed. Washington, DC: American Psychiatric Press; 2004:265-289.
50. Johnson RE, Jones HE, Jasinski DR, et al. Buprenorphine treatment of pregnant opioid-dependent women: maternal and neonatal outcomes. Drug Alcohol Depend. 2001;63:97-103.
51. Schindler SD, Eder H, Ortner R, et al. Neonatal outcome following buprenorphine maintenance during conception and throughout pregnancy. Addiction. 2003;98:103-110.
52. Jones HE, Johnson RE, Jasinski DR, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend. 2005;79:1-10.
53. Fischer G, Ortner R, Rohrmeister K, et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction. 2006;101:275-281.
54. Lejeune C, Simmat-Durand L, Gourarier L, et al. Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution. Drug Alcohol Depend. 2006;82:250-257.
55. Dole VP, Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction, a clinical trial with methadone hydrochloride. JAMA. 1965;193:646-650.
56. Dole VP, Nyswander ME, Kreek MJ. Narcotic blockade - a medical technique for stopping heroin use by addicts. Trans Assoc Am Physicians. 1966;79:122-136.
57. Dole VP, Nyswander ME, Warner A. Successful treatment of 750 criminal addicts. JAMA. 1968;206:2708-2711.
58. Ball JC, Ross A. The Effectiveness of Methadone Maintenance Treatment. New York, NY: Springer-Verlag; 1991.
59. Dole VP, Joseph H. Long-term outcome of patients treated with methadone maintenance. Ann N Y Acad Sci. 1978;311:181-189.
60. Harwood HJ, Hubbard RL, Collins JJ, et al. The costs of crime and the benefits of drug abuse treatment: a cost-benefit analysis using TOPS data. NIDA Res Monogr. 1988;86:209-235.
61. Amato L, Davoli M, C AP, et al. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat. 2005;28:321-329.
62. Schottenfeld RS. Opioids maintenance treatment. In: Galanter M, Kleber HD, eds. Textbook of Substance Abuse Treatment. 3rd ed. Washington, DC: American Psychiatric Press; 2004:291-304.
63. McLellan AT, Arndt IO, Metzger DS, et al. The effects of psychosocial services in substance abuse treatment. JAMA. 1993;269:1953-1959.
64. Gourevitch MN, Friedland GH. Interactions between methadone and medications used to treat HIV infection: a review. Mt Sinai J Med. 2000;67:429-436.
65. Clarke SM, Mulcahy FM, Tjia J, et al. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol. 2001;51:213-217.
66. Altice FL, Friedland GH, Cooney EL. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS. 1999;13:957-962.
67. McCance-Katz EF, Rainey PM, Friedland G, et al. The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. Clin Infect Dis. 2003;37:476-482.
68. Akerele EO, Levin F, Nunes E, et al. Effects of HIV triple therapy on methadone levels. Am J Addict. 2002;11:308-314.
69. Schottenfeld RS, Chawarski MC, Pakes JR, et al. Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. Am J Psychiatry. 2005;162:340-349.
70. Greenstein RA, Fudala, PJ, O'Brien CP. Alternative pharmacotherapies for opiate addiction. In: Lowinson JH, Ruiz P, Millma, RB, Langrod JG, eds. Substance Abuse: a Comprehensive Textbook. Baltimore, Md: Williams and Wilkins; 1997
71. Buster MC, van Brussel GH, van den Brink W. An increase in overdose mortality during the first 2 weeks after entering or re-entering methadone treatment in Amsterdam. Addiction. 2002;97:993-1001.
72. Donny EC, Walsh SL, Bigelow GE, et al. High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans. Psychopharmacology (Berl). 2002;161:202-212.
73. Strain EC, Bigelow GE, Liebson IA, et al. Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA. 1999;281:1000-1005.
74. Grabowski J, Creson D, Rhoades HM, et al. Moderate- vs high-dose methadone for opioid dependence. JAMA. 1999;282:2121-2;author reply 2122-2123.
75. Gerstein DR. Research: drug abuse. In: Galanter M, Kleber HD, eds. Textbook of Substance Abuse Treatment. 3rd ed. Washington, DC: American Psychiatric Press; 200:138-140.
76. Caplehorn JR, Bell J. Methadone dosage and retention of patients in maintenance treatment. Med J Aust. 1991;154:195-199.
77. Kleber HD, Gold MS. Use of psychotropic drugs in treatment of methadone maintained narcotic addicts. Ann N Y Acad Sci. 1978;311:81-98.
78. Kreek MJ. Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann N Y Acad Sci. 2000;909:186-216.
79. Kreek MJ. Medical complications in methadone patients. Ann N Y Acad Sci. 1978;311:110-134.
80. Kreek MJ, Koob GF. Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend. 1998;51:23-47.
81. Krantz MJ, Lewkowiez L, Hays H, et al. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med. 2002;137:501-504.
82. Fishbain DA, Cutler RB, Rosomoff HL, et al. Are opioid-dependent/tolerant patients impaired in driving-related skills? A structured evidence-based review. J Pain Symptom Manage. 2003;25:559-577.
83. Gruber SA, Tzilos GK, Silveri MM, et al. Methadone maintenance improves cognitive performance after two months of treatment. Exp Clin Psychopharmacol. 2006;14:157-164.
84. Brooner RK, Kidorf MS, King VL, et al. Comparing adaptive stepped care and monetary-based voucher interventions for opioid dependence. Drug Alcohol Depend. 2007;88 (suppl 2):S14-S23.
85. Schwartz RP, Highfield DA, Jaffe JH, et al. A randomized controlled trial of interim methadone maintenance. Arch Gen Psychiatry. 2006;63:102-109.
86. Schwartz RP, Jaffe JH, Highfield DA, et al. A randomized controlled trial of interim methadone maintenance: 10-month follow-up. Drug Alcohol Depend. 2007;86:30-36.
87. Murrill CS, Weeks H, Castrucci BC, et al. Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities. Am J Public Health. 2002;92:385-387.
88. Compton P, Charuvastra VC, Ling W. Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent. Drug Alcohol Depend. 2001;63:139-46.
89. Kantor TG, Cantor R, Tom E. A study of hospitalized surgical patients on methadone maintenance. Drug Alcohol Depend. 1980;6:163-173.
90. Alford DP, Compton P, Samet JH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med. 2006;144:127-134.
91. Mehta V, Langford RM. Acute pain management for opioid dependent patients. Anaesthesia. 2006;61:269-276.
92. Kling MA, Carson RE, Borg L, et al. Opioid receptor imaging with positron emission tomography and [(18)F]cyclofoxy in long-term, methadone-treated former heroin addicts. J Pharmacol Exp Ther. 2000;295:1070-1076.
93. Salsitz EA, Joseph H, Frank B, et al. Methadone medical maintenance: treating chronic opioid dependence in private medical practice-a summary report. Mt Sinai J Med. 2000;67:388-397.
94. Rosenblum AR, Magura, S, Joseph H. Ambivalence towards methadone treatment among intravenous drug users. J Psychoactive Drugs. 1991;23:21-27.
95. Harris KA, Jr, Arnsten JH, Joseph H, et al. A 5-year evaluation of a methadone medical maintenance program. J Subst Abuse Treat. 2006;31:433-438.
96. King VL, Kidorf MS, Stoller KB, et al. A 12-month controlled trial of methadone medical maintenance integrated into an adaptive treatment model. J Subst Abuse Treat. 2006;31:385-393.
97. Merrill JO, Jackson TR, Schulman BA, et al. Methadone medical maintenance in primary care. An implementation evaluation. J Gen Intern Med. 2005;20:344-349.
98. Novick DM, Joseph H, Salsitz EA, et al. Outcomes of treatment of socially rehabilitated methadone maintenance patients in physicians' offices (medical maintenance): follow-up at three and a half to nine and a fourth years. J Gen Intern Med. 1994;9:127-130.
99. Metzger DS, Woody GE, McLellan AT, et al. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr. 1993;6:1049-1056.
100. Zanis DA, Woody GE. One-year mortality rates following methadone treatment discharge. Drug Alcohol Depend. 1998;52:257-260.
101. Caplehorn JR, Dalton MS, Haldar F, et al. Methadone maintenance and addicts' risk of fatal heroin overdose. Subst Use Misuse. 1996;31:177-196.
102. Gold MS, Dackis CA, Washton AM. The sequential use of clonidine and naltrexone in the treatment of opiate addicts. Adv Alcohol Subst Abuse. 1984;3:19-39.
103. SAMHSA. Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. In: Treatment Improvement Protocol (TIP) Series 40. Rockville, Md: DHHS Publication No. (SMA) 04-3939; 2004.
104. Bloms-Funke P, Gillen C, Schuettler AJ, et al. Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor. Peptides. 2000;21:1141-1146.
105. Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349:949-958.
106. Strain EC, Stitzer ML, Liebson IA, et al. Dose-response effects of methadone in the treatment of opioid dependence. Ann Intern Med. 1993;119:23-27.
107. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA. 1992;267:2750-2755.
108. Johnson RE, Eissenberg T, Stitzer ML, et al. Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing. Drug Alcohol Depend. 1995;40:27-35.
109. Fiellin DA, Kleber HD, Trumble-Hejduk JG, et al. Consensus statement of office-based treatment of opioid dependence using buprenorphine. J Sub Abuse Treatment. 2004;27:153-159.
110. Torrington M, Domier CP, Hillhouse M, et al. Buprenorphine 101: Treating Opioid dependence with buprenorphine in an office-based setting. J Addict Dis. 2007;26:93-99.
111. Meier BR, Patkar AA. Buprenorphine treatment: factors and first-hand experiences for providers to consider. J Addict Dis. 2007;26:3-14.
112. Auriacombe M, Franques, P, Tignol J. Deaths attributable to methadone vs buprenorphine in France. JAMA. 2001:45.
113. Mendelson J, Upton RA, Everhart ET, et al. Bioavailability of sublingual buprenorphine. J Clin Pharmacol. 1997;37:31-37.
114. Strain EC, Moody DE, Stoller KB, et al. Relative bioavailability of different buprenorphine formulations under chronic dosing conditions. Drug Alcohol Depend. 2004;74:37-43.
115. Walsh SL, Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend. 2003;70(2 Suppl):S13-27.
116. Comer SD, Collins ED, Fischman MW. Intravenous buprenorphine self-administration by detoxified heroin abusers. J Pharmacol Exp Ther. 2002;301:266-276.
117. Obadia Y, Perrin V, Feroni I, et al. Injecting misuse of buprenorphine among French drug users. Addiction. 2001;96:267-272.
118. Partanen A, Maki J. Buprenorphine more common as a problem drug in Finland, Nordic Studies on Alcohol and Drugs. Nordisk Alkohl- & Narkoikatidskrift (NAT), English Supplement. 2004:156-161.
119. Sakol MS, Stark C, Sykes R. Buprenorphine and temazepam abuse by drug takers in Glasgow - an increase. Br J Addict. 1989;84:439-441.
120. Jenkinson RA, Clark NC, Fry CL, et al. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue? Addiction. 2005;100:197-205.
121. Alho H, Sinclair D, Vuori E, et al. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend. 2007;88:75-78.
122. Kobayashi K, Yamamoto T, Chiba K, et al. Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab Dispos. 1998;26:818-821.
123. Carrieri MP, Vlahov D, Dellamonica P, et al. Use of buprenorphine in HIV-infected injection drug users: negligible impact on virologic response to HAART. The Manif-2000 Study Group. Drug Alcohol Depend. 2000;60:51-54.
124. Bruce RD, McCance-Katz E, Kharasch ED, et al. Pharmacokinetic interactions between buprenorphine and antiretroviral medications. Clin Infect Dis. 2006;43 (suppl 4):S216-S223.
125. Bruce RD, Altice FL, Gourevitch MN, et al. Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J Acquir Immune Defic Syndr. 2006;41:563-572.
126. Mello NK, Mendelson JH, Kuehnle JC. Buprenorphine effects on human heroin self-administration: an operant analysis. J Pharmacol Exp Ther. 1982;223:30-39.
127. Comer SD, Collins ED, Fischman MW. Buprenorphine sublingual tablets: effects on IV heroin self-administration by humans. Psychopharmacology (Berl). 2001;154:28-37.
128. Johnson RE, Chutuape MA, Strain EC, et al. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med. 2000;343:1290-1297.
129. Kreek MJ, LaForge KS, Butelman E. Pharmacotherapy of addictions. Nat Rev Drug Discov. 2002;1:710-726.
130. attick RP, Kimber J, Breen C, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2003:CD002207.
131. Kakko J, Gronbladh L, Svanborg KD, et al. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry. 2007;164:797-803.
132. Kintz P. Deaths involving buprenorphine: a compendium of French cases. Forensic Sci Int. 2001;121:65-69.
133. Montoya ID, Gorelick DA, Preston KL, et al. Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin Pharmacol Ther. 2004;75:34-48.
134. Kosten TR, Kleber HD, Morgan C. Treatment of cocaine abuse with buprenorphine. Biol Psychiatry. 1989;26:637-639.
135. Strain EC, Stitzer ML, Liebson IA, et al. Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index. J Clin Psychopharmacol. 1996;16:58-67.
136. Schottenfeld RS, Pakes JR, Oliveto A, et al. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry. 1997;54:713-720.
137. Brooner RK, Kidorf MS, King VL, et al. Behavioral contingencies improve counseling attendance in an adaptive treatment model. J Subst Abuse Treat. 2004;27:223-232.
138. Magura S, Lee SJ, Salsitz EA, et al. Outcomes of buprenorphine maintenance in office-based practice. J Addict Dis. 2007;26:13-23.
139. Lofwall MR, Stitzer ML, et al. Comparative safety and side effect profiles of buprenorphine and methadone in the outpatient treatment of opioid dependence. Addict Disorders Treat. 2005;4:49-64.
140. Wedam EF, Haigney, MCP, et al. EKG QT-prolongation effects of methadone, LAAM, and buprenorphine in a randomized trial, in College on Problems of Drug Dependence Annual Conference. San Juan, Puerto Rico, 2004.
141. Dyer KR, Foster DJ, White JM, et al. Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships. Clin Pharmacol Ther. 1999;65:685-694.
142. Dyer KR, White JM, Foster DJ, et al. The relationship between mood state and plasma methadone concentration in maintenance patients. J Clin Psychopharmacol. 2001;21:78-84.
143. Roberts DM, Meyer-Witting M. High-dose buprenorphine: perioperative precautions and management strategies. Anaesth Intensive Care. 2005;33:17-25.
144. Becker AB, Strain EC, Bigelow GE, et al. Gradual dose taper following chronic buprenorphine. Am J Addict. 2001;10:111-121.
145. Amass L, Bickel WK, Higgins ST, et al. A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification. J Addict Dis. 1994;13:33-45.
146. Kosten TR, Kleber HD. Buprenorphine detoxification from opioid dependence: a pilot study. Life Sci. 1988;42:635-641.
147. Kosten TR, Morgan C, Kleber HD. Phase II clinical trials of buprenorphine: detoxification and induction onto naltrexone. NIDA Res Monogr. 1992;121:101-119.
148. O'Brien CP, Kampman, KM. Opioids: antagonists and partial agonists. In: Galanter M, Kleber HD. Textbook of Substance Abuse Treatment. 3rd ed. Washington, DC: American Psychiatric Publishing, Inc; 2004:305-319.
149. Kleber HD, Kosten TR, Gaspari J, et al. Nontolerance to the opioid antagonism of naltrexone. Biol Psychiatry. 1985;20:66-72.
150. Garbutt JC, Kranzler HR, O'Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293:1617-1625.
151. Comer SD, Sullivan MA, Yu E, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2006;63:210-218.
152. Washton AM, Pottash AC, Gold MS. Naltrexone in addicted business executives and physicians. J Clin Psychiatry. 1984;45:39-41.
153. O'Brien C, Cornish JW. Naltrexone for probationers and parolees. J Subst Abuse Treat. 2006;31:107-111.
154. Cornish JW, Henson D, Levine S. Naltrexone maintenance: Effect on morphine sensitivity in normal volunteers. Am J Addict. 1993;2:34-38.
155. Tennant FS, Jr, Rawson RA, Cohen AJ, et al. Clinical experience with naltrexone in suburban opioid addicts. J Clin Psychiatry. 1984;45:42-45.
156. Roth A, Hogan I, Farren C. Naltrexone plus group therapy for the treatment of opiate-abusing health-care professionals. J Subst Abuse Treat. 1997;14:19-22.
157. Krupitsky EM, Zvartau EE, Masalov DV, et al. Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. J Subst Abuse Treat. 2006;31:319-328.
158. Fudala PJ, Berkow LC, Fralich JL, et al. Use of naloxone in the assessment of opiate dependence. Life Sci. 1991;49:1809-1814.
159. Peachey JE, Lei H. Assessment of opioid dependence with naloxone. Br J Addict. 1988;83:193-201.
160. Carroll KM, Ball SA, Nich C, et al. Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement. Arch Gen Psychiatry. 2001;58:755-761.
161. Fals-Stewart W, O'Farrell TJ. Behavioral family counseling and naltrexone for male opioid-dependent patients. J Consult Clin Psychol. 2003;71:432-442.
162. Rothenberg JL, Sullivan MA, Church SH, et al. Behavioral naltrexone therapy: an integrated treatment for opiate dependence. J Subst Abuse Treat. 2002;23:351-360.
163. Nunes EV, Rothenberg JL, Sullivan MA, et al. Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness? Am J Drug Alcohol Abuse. 2006;32:503-517.
164. Preston KL, Silverman K, Umbricht A, et al. Improvement in naltrexone treatment compliance with contingency management. Drug Alcohol Depend. 1999;54:127-35.
165. Carroll KM. Recent advances in the psychotherapy of addictive disorders. Curr Psychiatry Rep. 2005;7:329-336.
166. Marrazzi MA, Wroblewski JM, Kinzie J, et al. High-dose naltrexone and liver function safety. Am J Addict. 1997;6:21-29.
167. Arndt ID, Cacciola JS, McLellan AT. A re-evaluation of naltrexone toxicity in recovering opiate addicts. In: Harris LS, ed. Problems of Drug Dependence. Rockville, Md: National Institute on Drug Abuse. NIDA Res Monogr. 1986:67:S25.
168. Pfohl DN, Allen JI, Atkinson RL, et al. Naltrexone hydrochloride (Trexan): a review of serum transaminase elevations at high dosage. NIDA Res Monogr. 1986;67:66-72.
169. Verebey K, Volavka J, Mule SJ, et al. Naltrexone: disposition, metabolism, and effects after acute and chronic dosing. Clin Pharmacol Ther. 1976;20:315-328.
170. Volavka J, Cho D, Mallya A, et al. Naloxone increases ACTH and cortisol levels in man. N Engl J Med. 1979;300:1056-1057.
171. Mendelson JH, Ellingboe J, Kuehnle J, et al. Heroin and naltrexone effects on pituitary-gonadal hormones in man: tolerance and supersensitivity. NIDA Res Monogr. 1979;27:302-308.
172. Mendelson JH, Ellingboe J, Keuhnle JC, et al. Effects of naltrexone on mood and neuroendocrine function in normal adult males. Psychoneuroendocrinology. 1978;3:231-236.
173. Kirchmayer U, Davoli M, Verster A. Naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev. 2003: CD001333.
174. Bartu A, Freeman NC, Gawthorne GS, et al. Characteristics, retention and readmissions of opioid-dependent clients treated with oral naltrexone. Drug Alcohol Rev. 2002;21:335-340.